Celecoxib
Trovati 34 articoli
- Knee osteoarthritis: Glucosamine and/or Chondroitin no better than placebo in slowing structural damage
- The dietary supplements Glucosamine and Chondroitin sulfate, together or alone, appeared to fare no better than placebo in slowing loss of cartilage in osteoarthritis of the knee, researchers from the Glucosamine / Chondroitin Arthritis Intervention Trial ( GAIT ) team report in the Arthritis & R... (Leggi Articolo)
- Coronary artery disease: Celecoxib after stent implantation can reduce the need for revascularisation of the target lesion
- The adjunctive use of Celecoxib ( Celebrex ) for 6 months after stent implantation in patients with coronary artery disease is safe and can reduce the need for revascularisation of the target lesion. In-vitro and animal experiments have shown that the cyclo-oxygenase 2 inhibitor Celecoxib can ... (Leggi Articolo)
- ADRAC: drug-induced pancreatitis
- Gallstones and alcohol are the two most common causes of pancreatitis, but medicines are estimated to account for about 2 to 5% of cases. ADRAC ( Adverse Drug Reactions Advisory Committee ) has received 414 such reports, implicating 695 medicines. Time to onset varied from the first day of use t... (Leggi Articolo)
- Selective COX-2 inhibitors linked to risk of myocardial infarction
- Researchers at University of Manchester, UK, evaluated the risk of myocardial infarction associated with the use of selective cyclooxygenase-2 ( COX-2 ) inhibitors ( coxibs ). A systematic review and meta-analysis of randomised controlled trials ( RCT s) were performed. Fifty-five trials ( 9... (Leggi Articolo)
- Dormant inflammatory bowel disease: painkillers effective
- Two studies, published in the Clinical Gastroenterology and Hepatology, have showen that prescription painkillers are effective in easing the pain of patients with dormant inflammatory bowel disease ( IBD ) and are not likely to cause symptom flare-ups in IBD patients in remissions. Both studi... (Leggi Articolo)
- Efficacy of Glucosamine, Chondroitin sulfate in patients with moderate to severe osteoarthritis knee pain
- The dietary supplements Glucosamine and Chondroitin sulfate proved no better than a placebo in relieving osteoarthritis knee pain in most participants of a major national trial. But the study, published in the New England Journal of Medicine ( NEJM ), also showed a smaller subgroup of trial patie... (Leggi Articolo)
- New evidence on risks associated with Cox-2 inhibitors and NSAIDs
- Two review studies evaluating the safety of the selective cyclooxygenase 2 ( COX-2 ) inhibitors and non-steroidal anti-inflammatory drugs ( NSAIDs ) have found increased cardiovascular and kidney risks. It is estimated that more than 30 million people worldwide take NSAIDs daily for treatment ... (Leggi Articolo)
- COX-2 inhibitors reduce risk of cancer
- Results from a five-year study have shown that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers. " We believe this is the first study to show that sel... (Leggi Articolo)
- Meloxicam linked to higher risk of adverse cardiovascular events than Celecoxib and Rofecoxib
- Researchers at the National Yang-Ming University, Taipei, ( Taiwan ) assessed the risk of acute myocardial infarction, angina, stroke and transient ischaemic attack ( TIA ) in long-term users of Rofecoxib ( Vioxx ) and Celecoxib ( Celebrex ), and compared this data with that for those using Melox... (Leggi Articolo)
- Genetics plays a role in the side effects experienced by patients taking COX-2 inhibitors
- A study published in the journal Gastroenterology found a difference in how people responded to COX-2 inhibitors and that up to 30 percent of this variability can be attributed to an individual's genetic make-up. This variation can influence both how useful the drugs are in affording relief fro... (Leggi Articolo)
- Post-myocardial infarction: risk of death linked to COX-2 inhibitors and non-selective NSAIDs
- Myocardial infarction survivors taking COX-2-selective (NSAIDs) inhibitors or high dosages of nonselective nonsteroidal antiinflammatory drugs ( NSAIDs ) are at a greater risk of a second myocardial infarction or death. The study, led by Gunnar H. Gislason, at Gentofte University Hospital, DK-... (Leggi Articolo)
- Risk of acute myocardial infarction is a class effect of COX-2 inhibitors
- The cardiovascular safety of cyclooxygenase ( COX )-2–selective nonsteroidal antiinflammatory drugs ( NSAIDs ) has come under scrutiny after the withdrawal of Rofecoxib ( Vioxx ) and halting of the Adenoma Prevention with Celecoxib ( Celebrex ) trial. It is unknown whether the newer second-ge... (Leggi Articolo)
- Relationship between inflammatory processes and tumor formation
- Researchers are closely studying the link between inflammatory processes and tumor formation, while others are investigating anti-inflammatory drugs as a means to prevent and treat cancer. Antihistamine and anti-inflammatory drug use associated differently for high-grade versus low-grade gli... (Leggi Articolo)
- Celecoxib for juvenile rheumatoid arthritis, FDA approved
- The FDA ( Food and Drug Administration ) has approved Celebrex ( Celecoxib ) for a new use: the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients two years of age and older. Juvenile rheumatoid arthritis is an autoimmune disease that affects approximately 30,000 to ... (Leggi Articolo)
- Increased risk for non-Hodgkin lymphoma with regular use of COX-2 inhibitors
- Researchers at the University of California School of Medicine, San Francisco, have examined the association between long-term use of nonsteroidal antiinflammatory drugs ( NSAIDs ) and non-Hodgkin lymphoma ( NHL ), using data collected between October 2001 and May 2004 in an ongoing population-ba... (Leggi Articolo)
- Vioxx: heart attack can occur within the first two weeks of use
- A study by investigators at the McGill University Health Centre ( MUHC ) found that a quarter of patients who suffered a myocardial infarction while taking Vioxx ( Rofecoxib ) did so within the first two weeks of taking the drug. The research, published in the Canadian Medical Association Jo... (Leggi Articolo)
- Selective inhibitors of mPGES-1, a new class of anti-inflammatory drugs that might lessen chance of COX-2 cardiovascular events
- Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which drugs like Celebrex and Vioxx cause heart problems, in multiple animal models. The findings offer the prospect of a new generation of anti-inflammatory drugs that bypass this issue. ... (Leggi Articolo)
- Selective inhibitors of mPGES-1, a new class of anti-inflammatory drugs that might lessen chance of COX-2 cardiovascular events
- Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which drugs like Celebrex and Vioxx cause heart problems, in multiple animal models. The findings offer the prospect of a new generation of anti-inflammatory drugs that bypass this issue. ... (Leggi Articolo)
- Celebrex inhibits prostate tumor growth
- Selective cyclooxygenase-2 ( COX-2 ) inhibitors may suppress carcinogenesis by both COX-2-dependent and COX-2-independent mechanisms. Researchers at the Weill Medical College of Cornell University, New York, evaluated whether Celecoxib ( Celebrex ) or Rofecoxib ( Vioxx ), two selective COX-2 ... (Leggi Articolo)
- APC study, cardiovascular risk associated with Celecoxib
- Adenoma Prevention with Celecoxib ( APC ) study investigators reviewed all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who were enrolled in a trial comparing two doses of Celecoxib ( 200 mg or 400 mg twice daily ) with placebo for the preve... (Leggi Articolo)
- Risk of myocardial infarction in patients taking anti-inflammatory drugs
- A study has showed that Ibuprofen ( Brufen ) and other commonly used non-steroidal anti-inflammatory drugs ( NSAIDS ) for treating inflammation may increase the risk of heart attack. Patients should not stop taking the drugs involved, but further investigation into these treatments is needed,... (Leggi Articolo)
- Lung cancer chemoprevention trial with Celebrex
- The University of Texas M. D. Anderson Cancer Center has reactivated a lung cancer chemoprevention trial studying Celecoxib, an anti-inflammatory medication also known as Celebrex. M. D. Anderson voluntarily suspended the trial with Celebrex last December at the request of Pfizer, the maker of... (Leggi Articolo)
- Cox-2 inhibitors: prescribing restrictions for all drugs
- After evaluation of the available data, and consideration of submissions from patients and health professionals, the Medicines Adverse Reactions Committee ( MARC ) has recommended that the COX-2 inhibitors Celecoxib ( Celebrex ), Etoricoxib ( Arcoxia ), Lumiracoxib ( Prexige ), Meloxicam ( Mobic ... (Leggi Articolo)
- Ankylosing spondylitis, benefits of continuous NSAID use
- Study suggests continuous NSAID treatment more effectively reduces X-Ray progression than intermittent treatment. A widely under-recognized form of arthritis, ankylosing spondylitis ( AS ) is a chronic, progressive disease targeting the spine. Commonly striking in young adulthood, before age ... (Leggi Articolo)
- Can most types of cancers be prevented ?
- Debate exists on how many cancer deaths are preventable in principle - estimates range from 50 percent to 80 percent - but most researchers agree that tobacco use ( mostly smoking ) accounts for the majority. Today, cigarette smoking claims about 438,000 premature deaths in the U.S. annually. It ... (Leggi Articolo)
- FDA: Celebrex for the treatment of ankylosing spondylitis
- The FDA ( Food and Drug Administration ) has approved the selective COX-2 inhibitor Celebrex ( Celecoxib ) for the relief of the signs and symptoms associated with ankylosing spondylitis, a form of arthritis that affects the spine. Celebrex continues to be an treatment option for patients su... (Leggi Articolo)
- No evidence that COX-2 inhibitors provide greater gastroprotection
- A study, published in the BMJ, found no evidence to claims that the new generation of anti-inflammatory drugs ( COX-2 inhibitors ) are less harmful to the stomach lining than many traditional anti-inflammatory drugs. These drugs were specifically designed to provide pain relief without the ser... (Leggi Articolo)
- iNOS-based inflammation pathway is cross-linked with COX-2 pathway
- An identified path of inflammation once thought to be wholly independent of other inflammatory systems has now been linked to another major pathway. The findings by neuroscientists at Johns Hopkins are likely to point scientists to novel drugs that significantly reduce the risks of taking COX-2 ... (Leggi Articolo)
- FDA, changes to the class of non-steroidal anti-inflammatory drugs
- The FDA ( Food and Drug Administration ) announced a series of important changes pertaining to the marketing of the non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription ( over-the-counter, OTC ) non-selective NSAID medications. FDA h... (Leggi Articolo)
- NSAIDs might be associated with increased breast carcinoma risk
- Researchers at the Keck School of Medicine of the University of Southern California, Los Angeles, found that women using Ibuprofen every day for five years or longer were more than 50 percent more likely than non-users to be diagnosed with breast cancer, while women using Aspirin every day for fi... (Leggi Articolo)
- Anti-inflammatory drugs: COX-2 inhibitors associated with blood pressure elevation
- An analysis of 19 randomized controlled trials involving COX-2 inhibitors ( selective cyclooxygenase-2 inhibitors ) suggests that these agents raise blood pressure more than either conventional nonsteroidal anti-inflammatory drugs ( NSAIDs ) or placebo. NSAIDs, among the most widely prescribed... (Leggi Articolo)
- Anti-inflammatory drugs: how COX-2 inhibitors can lead to heart disease
- Researchers from University of Pennsylvania School of Medicine have found additional evidence that may help explain how selective inhibitors of COX-2 might predispose individuals to heart disease and stroke. A study, published in Circulation Research, reports that a COX-2-derived fatty substan... (Leggi Articolo)
- Acetylsalicylic acid may reduce risk of colon tumor recurrence and death
- A study led by researchers at Dana-Farber found that Acetylsalicylic acid ( Aspirin ) has a potential treatment benefit in people who have colon cancer. The patients who took Aspirin regularly have a decreased risk of disease recurrence and death by half compared to non-users, after surgery. ... (Leggi Articolo)
- National Cancer Institute has stopped a clinical trial of the Cox-2 inhibitor Celecoxib
- The FDA released the following statement on the halting of a clinical trial of the Cox-2 inhibitor Celebrex ( celecoxib ): The Food and Drug Administration (FDA) learned from the National Cancer Institute ( NCI ) and Pfizer, Inc., that NCI has stopped drug administration in an ongoing clinical... (Leggi Articolo)
